Head and Neck Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Advaxis, Alkermes, ALX Oncology, AstraZeneca, Bayer, BioAtla, Celldex

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the Head and Neck Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Head and Neck Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Head and Neck Cancer Market

The Head and Neck Cancer Pipeline report embraces in-depth commercial, regulatory, and Head and Neck Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Head and Neck Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Head and Neck Cancer Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for Head and Neck Cancer treatment and the aggregate therapies developed by major pharma companies.

It accesses the different Head and Neck Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the major Head and Neck Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the Head and Neck Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Head and Neck Cancer therapeutic market.

Analysis of Emerging Head and Neck Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Head and Neck cancer pipeline report provide the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as





Intravenous/ Subcutaneous





Molecule Type

Products have been categorized under various Molecule types such as


Antisense oligonucleotides


Monoclonal antibody



Recombinant protein

Small molecule

Stem Cell


Learn How the Head and Neck Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @


Head and Neck Cancer Therapeutics Landscape

There are approx. 150+ key companies developing therapies for Head and Neck cancer. Currently, Innate Pharma is leading the therapeutics market with its Head and Neck cancer drug candidates in the most advanced stage of clinical development. 

Head and Neck Cancer Companies Actively Working in the Therapeutic Market Include:

Adlai Nortye Biopharma Co., Ltd., Advaxis, Inc., Alkermes, Inc., ALX Oncology, Arcus Biosciences, Inc., Astex Pharmaceuticals, Inc., AstraZeneca, Aveta Biomics, Inc., Bayer HealthCare, Betta Pharmaceuticals Co., Ltd., Bicycle Therapeutics, BioAtla, Inc., BioNTech SE, Boehringer Ingelheim, Carisma Therapeutics Inc, Celldex Therapeutics, Cellectar Biosciences, Inc., Checkpoint Therapeutics, Inc., Compugen Ltd, Corregene Biotechnology Co., Ltd, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cue Biopharma, Cyteir Therapeutics, Inc., CytomX Therapeutics, Debiopharm, Eli Lilly and Company, Galectin Therapeutics, Genentech, Inc., GlaxoSmithKline, I-Mab Biopharma, Ikena Oncology, Immutep S.A.S., Incyte Corporation, Inhibrx, Inc., Innate Pharma, Intensity Therapeutics, Inc., IntraGel Therapeutics, iTeos Belgium SA, Jacobio Pharmaceuticals Co., Ltd., Klus Pharma Inc., Kura Oncology, MacroGenics, Memgen, Inc., Merck KGaA, Merus N.V., Nanobiotix, NanoCarrier Co., Ltd., Nektar Therapeutics, Palleon Pharmaceuticals, Inc., Pfizer, Pionyr Immunotherapeutics Inc., PNP Therapeutics, Inc., Quadriga Biosciences, Inc., Rapa Therapeutics, Roche, Rubius Therapeutics, Shanghai Henlius Biotech, SN BioScience, Takeda Oncology, Transgene, TyrNovo Ltd., Vaccinex, Wellmarker Bio, and many others.

Emerging and Marketed Head and Neck Cancer Drugs Covered in the Report Include:

Monalizumab: Innate Pharma

Niraparib: GlaxoSmithKline

Xevinapant: Debiopharm

Enoblituzumab: MacroGenics

TECENTRIQ (Atezolizumab): Hoffmann-La Roche

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

XEVINAPANT (debio 1143): Merck KGaA

Toripalimab: Junshi Biosciences/Coherus

Tipifarnib: Kura Oncology

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Head and Neck Cancer Companies Working in the Market @ 


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Head and Neck Cancer Treatment Patterns

4. Head and Neck Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Head and Neck Cancer Late Stage Products (Phase-III)

7. Head and Neck Cancer Mid-Stage Products (Phase-II)

8. Head and Neck Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Head and Neck Cancer Discontinued Products

13. Head and Neck Cancer Product Profiles

14. Major Head and Neck Cancer Companies in the Market

15. Key Products in the Head and Neck Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Head and Neck Cancer Unmet Needs

18. Head and Neck Cancer Future Perspectives

19. Head and Neck Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports By DelveInsight

Diabetes Market

“Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Diabetes market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: